The company's core technology involves using chimeric antigen receptor (CAR)-natural killer (NK) immunotherapy to target the cancer cell surface marker CD147. By re-engineering NK cells and developing proprietary methods to expand 'off-the-shelf' NK and CAR-NK cells, NAKI Therapeutics aims to provide a more effective and scalable treatment for hepatocellular carcinoma (HCC) and other solid tumors. The company was founded in 2020 and is headquartered in Summit, New Jersey.